Celyad, Ono Pharmaceutical deal

Celyad granted Ono exclusive rights to develop and commercialize its allogeneic NKR2 T-cell immunotherapy in Japan, Korea and Taiwan. The deal includes an option for autologous NKR2 T-cell. The NKR-2...